Khoso Baluch Buys 104,166 Shares of CorMedix Inc. (CRMD) Stock

CorMedix Inc. (NYSEAMERICAN:CRMD) CEO Khoso Baluch purchased 104,166 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was acquired at an average cost of $0.48 per share, for a total transaction of $49,999.68. Following the completion of the purchase, the chief executive officer now owns 225,373 shares in the company, valued at approximately $108,179.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CorMedix Inc. (CRMD) traded down $0.01 during midday trading on Thursday, hitting $0.56. The stock had a trading volume of 727,869 shares, compared to its average volume of 678,652. CorMedix Inc. has a fifty-two week low of $0.32 and a fifty-two week high of $2.48.

CRMD has been the topic of a number of research analyst reports. Zacks Investment Research raised CorMedix from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research note on Friday, September 8th. HC Wainwright set a $4.00 price target on CorMedix and gave the stock a “buy” rating in a research note on Monday, October 16th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of CorMedix by 3.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock valued at $518,000 after purchasing an additional 35,148 shares in the last quarter. Susquehanna International Group LLP lifted its stake in shares of CorMedix by 11,785.4% in the 2nd quarter. Susquehanna International Group LLP now owns 2,067,973 shares of the biotechnology company’s stock valued at $886,000 after purchasing an additional 2,085,670 shares in the last quarter. Elliott Management Corp lifted its stake in shares of CorMedix by 177.8% in the 2nd quarter. Elliott Management Corp now owns 4,166,868 shares of the biotechnology company’s stock valued at $1,785,000 after purchasing an additional 2,666,668 shares in the last quarter. Finally, Sabby Management LLC acquired a new position in shares of CorMedix in the 2nd quarter valued at about $1,818,000.

TRADEMARK VIOLATION WARNING: “Khoso Baluch Buys 104,166 Shares of CorMedix Inc. (CRMD) Stock” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://stocknewstimes.com/2017/12/14/khoso-baluch-buys-104166-shares-of-cormedix-inc-crmd-stock.html.

About CorMedix

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Insider Buying and Selling by Quarter for CorMedix (NYSEAMERICAN:CRMD)

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply